No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust

Some dividend yields look generous right up until the moment they get cut, but a handful of companies have funded unbroken payout streaks through recessions, patent cliffs, and commodity shocks. Three of them are still raising their dividends today.

Published October 30, 2026, 11:50am ET · 5 min read

A green and yellow retail display stand is filled with large, green plastic bottles of Gain laundry detergent and fabric softener. The top shelves hold Gain +ultra OXI detergent, the middle shelves feature Gain +odor defense detergent, and the bottom shelves display Gain fabric softener. Some shelves show empty slots, and price tags are visible, along with a QR code on the side of the display.
Large bottles of Gain laundry detergent and fabric softener, a Procter & Gamble brand, are prominently displayed in a retail store aisle. Visible price tags underscore the consumer spending landscape as P&G navigates growth targets and potential tariff concerns. © Courtesy of Mike Edmisten via 24/7 Wall St.

On Halloween eve, the scariest thing an income investor can find is a yield that looks generous but is stressed. That payout is one the business can barely fund, and it tends to get cut at the worst moment. The treats are the opposite. Johnson & Johnson (NYSE: JNJ) | JNJ Price Prediction, Procter & Gamble (NYSE: PG) and Coca-Cola (NYSE: KO) each pass three tests: free cash flow covers the dividend, debt is manageable, and the payout record holds up against real dividend history. To show how deep that record goes, P&G just finished its 70th consecutive year of dividend increases.

Johnson & Johnson: A Healthcare Giant Whose Cash Flow Carries the Dividend

J&J runs two businesses. Innovative Medicine makes drugs for cancer, immune diseases and neuroscience, and MedTech sells heart devices, surgical tools, vision care and orthopaedics. Innovative Medicine brought in $16.38B, up 7.8% during the second quarter, and MedTech added $8.93B, up 4.5%. Oncology grew 17.3%, led by DARZALEX at $4.21B.

Yield: The annualized forward dividend is $5.36 per share. With shares at $276.95, that works out to about a 1.94% yield. The yield looks thin mostly because the stock is up 35.98% year to date. Anyone who bought earlier is taking in much more on their original cost.

Payout coverage: In 2025, J&J produced $24.53 billion of operating cash flow and spent $4.832 billion on capital projects. That left about $19.7 billion of free cash flow against $12.381 billion in dividends, so the payout used roughly 63% of free cash flow. The pattern held through the first nine months of this year: $15.118 billion of free cash flow against $9.585 billion of dividends. Reported net income fell to $210 million in the September quarter, but operating cash flow still came in at $7.72 billion. That quarter’s dividend cost $3.227 billion. Dividends are paid out of cash, and the cash kept coming in.

Balance sheet and track record: J&J is known for an AAA-rated balance sheet, and its sales are spread across many drugs and devices, so no single product supports the dividend. The board raised the quarterly payout by 3.1% to $1.34, marking 64 consecutive years of dividend increases. The dividend history shows the quarterly amount climbing from $0.205 in 2002 to $1.19 in 2023, $1.24 in 2024, $1.30 in 2025, and $1.34 in 2026. The company declared its upcoming $1.34 payment on October 13 and has scheduled it for December 8.

Why trust it: Free cash flow covers the dividend with room to spare, newer drugs are growing, and the raise streak has lasted through recessions, patent cliffs, and lawsuits; for a retiree, that adds up to a reliable quarterly check.

Risk: STELARA, once a blockbuster, is losing sales to cheaper biosimilar copies. Its revenue fell 55.2% to $740M in the second quarter, so newer drugs have to keep growing quickly to replace it.

Procter & Gamble: Household Brands That Fund Seven Decades of Raises

P&G makes the everyday products people keep buying in good times and bad. It sells in roughly 65 countries through five segments, with brands such as Tide, Pampers, Gillette, Charmin and Crest. All five segments posted organic growth in the fiscal first quarter, and Beauty, Grooming, and Fabric & Home Care each grew 5%.

Yield: The annualized forward dividend is $4.354. With the stock at $162.87, the yield is about 2.67%, the highest of these three.

Payout coverage: P&G produced $15.84B of free cash flow in fiscal 2026, up 12.74%, and covers $10.232 billion in dividends. That means the dividend used about 65% of free cash flow. The new fiscal year started the same way, with $4.401 billion of free cash flow against $2.603 billion in dividends. Core EPS of $2.00 beat the $1.89 estimate. Management expects fiscal 2027 core EPS of $6.89 to $7.11 and plans to pay over $10 billion in dividends along with roughly $5B in buybacks.

Balance sheet and track record: P&G finished the quarter with $15.37B in cash, up 37.5% from a year earlier, and $55.34B of shareholders’ equity. Its record is the longest of the three: 70th consecutive year of dividend increases and 136th consecutive year of dividend payments. The dividend history shows an unbroken run of quarterly payments since 1999, with the quarterly amount rising from $0.28 in 2005 to $1.0885 now. Its most recent increase raised the payout from $1.0568, and the next payment comes November 16.

Why trust it: People buy detergent, diapers, and toothpaste, no matter what the economy is doing. That steady demand turns into steady cash, and P&G has used it to raise the dividend every year for 70 years.

Risk: Costs are rising. P&G expects an after-tax commodity cost headwind of about $1.4B in fiscal 2027, plus roughly $300M of higher net interest expense, and core gross margin already slipped 150 bps. That pressure could keep future increases small.

Coca-Cola: An Asset-Light Beverage Machine With Rising Free Cash Flow

Coca-Cola sells drinks in more than 200 countries and territories. Its brands include Coca-Cola, Sprite, Fanta, Powerade, Costa, and fairlife. Most of its revenue comes from selling concentrate to independent bottlers, so it needs relatively few factories and trucks. That keeps returns high: return on equity runs about 46.0% and operating margin about 28.7%.

Yield: Coca-Cola yields about 2.2%, based on an annualized forward dividend of $2.12. Shares trade near $94.46 after a 37.75% gain so far this year.

Payout coverage: In the first nine months of this year, Coca-Cola generated about $11.408 billion of free cash flow and covered $6.842 billion in dividends. The payout used roughly 60% of free cash flow. Management also raised its full-year free cash flow outlook to at least $13.0B, up from about $12.4B. Third-quarter adjusted EPS of $0.91 beat the $0.88 estimate, and global unit case volume grew 5%.

Balance sheet and track record: Coca-Cola supports more debt than its peers here, but the load is manageable. The debt-to-equity ratio is 1.47, net debt is 2.49 times EBITDA, and operating profit covers interest expense 8.32 times. The company has raised its dividend for 60+ consecutive years. The recent history confirms the pattern, with the quarterly payout rising each year from $0.41 in 2020 to $0.42, $0.44, $0.46, $0.485, $0.51 and $0.53 in 2026. The company declared its upcoming $0.53 payment on October 15 and scheduled it for December 15.

Why trust it: Free cash flow covers the dividend and is still growing, Coca-Cola Zero Sugar grew 16%, and the company has raised its payout every year for more than six decades.

Risk: Coca-Cola is in an ongoing tax dispute with the IRS, and a ruling against the company could have a potentially significant impact. A large payment would take cash that otherwise supports dividend growth.

Three Treats Built for Dependable Retirement Income

Johnson & Johnson, P&G and Coca-Cola offer moderate yields, and that restraint is why their dividends are reliable. Each pays out well under its free cash flow, keeps debt under control, and has a dividend history measured in decades. On a night built for tricks, these three give an income portfolio a payout it can count on.

Contact [email protected] for any questions or corrections.

Lee Jackson

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad, diverse career, including a stint as creative services director at an NBC affiliate in Austin, Texas, gives him unique insight into the financial industry.

Lee Jackson's journey in the financial industry spans more than 30 years, including nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career spanned pivotal sell-side Wall Street events, from the dot-com rise and bubble to the Long-Term Capital Management debacle, 9/11, and the Great Recession of 2008. This reflects his resilience and adaptability amid market volatility.

Lee Jackson’s practical financial industry experience, gained through a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing across various platforms. This unique combination allows him to shed light on the intricacies of Wall Street in a way only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.

All articles →